Elicera Therapeutics has signed an agreement with Baylor College of Medicine (BCM), Center for Cell & Gene Therapy regulating contract manufacturing of ELC-201, the company’s oncolytic virus armed with Elicera’s

Calliditas Therapeutics has announced that the US Food and Drug Administration (FDA) has approved TARPEYO (budesonide) delayed release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN)

Xbrane Biopharma has announced the initiation of developing two new biosimilar candidates referencing Keytruda and Darzalex respectively. Together with the continued development of Xdivane, a biosimilar candidate referencing Opdivo, this

Ultimovacs has announced that the U.S. Food and Drug Administration has granted orphan drug designation (ODD) for the company’s universal cancer vaccine UV1 for the treatment of stage IIB –

The new name and identity signifies a new phase of growth for the company and the agreement with US-based Regeneron is worth up to 900 million USD. The multi-target license

Affibody has announced a partnership agreement with ACELYRIN to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple autoimmune diseases. Under the terms of the agreement, Affibody

BerGenBio has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for bemcentinib in combination with an anti-PD-(L)1 agent as treatment for patients with STK11

The US-Scandinavian real estate entrepreneur Rutger Arnhult has, via his private company M2 Asset Management AB, agreed to invest in New York based Intrance Medical Systems Inc. “Investing in the

Oncopeptides has decided to reduce the activity level in the clinical development program with melflufen (INN melphalan flufenamide) to increase the company’s cash runway and at the same time support

Abera Bioscience initiates collaboration with an American university to accelerate the development of a vaccine candidate based on the company’s latest vaccine platform comprising protein bodies. The study will be

ApoGlyx has just closed a 6 million SEK investment round, coming from Almi Invest as well as from Swedish and Danish private investors. This new capital will allow the company

Ultimovacs has announced that its universal cancer vaccine, UV1, in combination with checkpoint inhibitors has received Fast Track designation from the U.S. FDA in the treatment of unresectable or metastatic

The two companies have announced a collaborative agreement for the development, manufacture, and supply of CT83 (KK-LC-1) mAb. These will be used to develop a diagnostic test to identify tumors

Cantargia has announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has issued a positive opinion for orphan designation of nadunolimab (CAN04) for treatment

Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro platform for antibody discovery against GPCRs, ion channels, and transporters. The collaboration enables AbCellera